The first FDA dog longevity drug is coming.
Track both major dog longevity approaches in one place: Loyal's LOY pipeline and Dog Aging Project TRIAD rapamycin research. FursBliss is not affiliated with Loyal, Dog Aging Project, NIH, or the FDA.
Latest public update: FDA reviewers accepted Target Animal Safety (TAS) on Jan 13, 2026. LOY-002 now has efficacy + safety accepted, with manufacturing review remaining before XCA filing. Conditional approval could arrive as early as 2026 depending on manufacturing review timing.
Source: BusinessWire Jan 2026 updateLOY-002 targets senior dogs aged 10+ years and 14+ lbs. Run a quick check below.
Drug availability and final label details may change with FDA review.
Loyal has three public longevity programs in motion: LOY-001, LOY-002, and LOY-003.
LOY-002 is designed as a caloric-restriction mimetic to support healthy aging pathways in senior dogs.
Public reporting now suggests conditional approval timing could land as early as 2026, while manufacturing review is still a gating step.
Get notified when LOY-002 updates
Be first to know about approval milestones, manufacturing updates, and potential availability timelines.
Loyal pipeline comparison
Drug snapshot
Target: Large/giant dogs, 7+ years, 40+ lbs
Format: Injectable (veterinarian-administered)
FDA status: RXE accepted Nov 2023
Outlook: Market target: 2026
Drug snapshot
Target: Senior dogs, 10+ years, 14+ lbs
Format: Prescription daily oral therapy
FDA status: Efficacy + safety accepted; manufacturing review pending
Outlook: Conditional approval could arrive in 2026
Drug snapshot
Target: Large/giant dogs, 7+ years, 40+ lbs
Format: Prescription pill alternative
FDA status: In development
Outlook: Under active pipeline development
LOY-002 vs TRIAD Rapamycin
| Category | LOY-002 (Loyal) | Rapamycin (TRIAD / Dog Aging Project) |
|---|---|---|
| Type | Daily pill | Weekly pill (research protocol) |
| Mechanism | Caloric restriction mimetic | mTOR inhibitor |
| Age target | 10+ years | 7+ years |
| Weight target | 14+ lbs | 44+ lbs |
| Trial size | 1,300 dogs (STAY) | 580 target (180+ enrolled as of Feb 2026) |
| Regulatory path | Toward FDA conditional approval | Research trial (not an FDA approval program) |
| Timeline | Conditional approval could be 2026 to 2027 | Trial follow-up through 2029 (study end Nov 2029) |
| Funding source | Private venture funding ($250M+) | $7M NIH funding for TRIAD progression |
FDA status tracker
Loyal
Status: In Progress
Safety + Manufacturing underway
1/3 milestones completed
- • 2023-11: RXE Accepted
- • 2026: Conditional Approval (est.)
Updated: Sun Feb 08 2026
Est. approval: 2026
Loyal
Status: Safety Accepted
TAS accepted Jan 13, 2026
2/3 milestones completed
- • 2025-02: RXE Accepted
- • 2026-01: TAS Accepted
- • 2026-2027: Conditional Approval (est.)
Updated: Sun Feb 08 2026
Est. approval: 2026-2027
• TAS accepted by FDA CVM on Jan 13, 2026.
• STAY study enrollment completed: 1,300 dogs across 70 clinics.
• No clinically significant adverse events at 1x, 3x, and 5x doses.
• Field safety dataset included 400+ dogs.
• Loyal now reports $250M+ total funding raised.
• Series C: $100M raised Feb 11, 2026, led by age1 (Laura Deming's Longevity Fund) and Baillie Gifford.
• Manufacturing technical section remains in progress.
• Loyal has publicly signaled XCA filing expectation in 2027.
• LOY-001 for large dogs is also anticipated for market in 2026.
• LOY-003 is a pill program for large and giant breed longevity support.
• STAY study sampling includes a longitudinal biobank (saliva + blood) that may accelerate future insights.
• Full approval follows STAY study completion.
Dates reflect public company communications and may change.
Drug deep dives
LOY-001 targets dogs 7+ years and 40+ lbs. The mechanism is focused on reducing overexpression of IGF-1 and growth hormone after maturity.
FDA status: RXE accepted in November 2023. Loyal has publicly signaled a 2026 market target.
Expected format: injectable, administered by a veterinarian.
Stay updated on LOY-001
LOY-003 targets the same large/giant population as LOY-001 but is being developed as a daily prescription pill.
Mechanism: same longevity pathway strategy as LOY-001 with a pill-based format for daily use under veterinary guidance.
Current status: in development.
Stay updated on LOY-003
Conditional approval could come as early as 2026 based on current public timelines, while manufacturing section review remains a key milestone.
STAY study enrollment is complete with 1,300 dogs across 70 clinics, launched Dec 2023 with an expected ~4 year duration.
Loyal has also communicated plans for a longitudinal biobank from STAY samples to support deeper longevity insights.
Sources: Loyal public updates, BusinessWire announcements, dvm360 (Feb 2026), and additional public reporting. Milestones can change with FDA review.
Rapamycin is an mTOR-pathway inhibitor being tested for potential healthspan and lifespan effects in aging dogs.
The Dog Aging Project published TRIAD methodology in GeroScience, framing it as a rigorous pharmacologic aging-intervention test in real-world companion dogs.
TRIAD is still enrolling dogs (7+ years, 44+ lbs) across 20 trial sites, targeting 580 total with about 180 enrolled so far. Medication is projected to begin in spring 2026, and the study is expected to conclude in Nov 2029.
Prior Dog Aging Project work reported small-dose rapamycin signals for improved cardiac function, supporting continued investigation.
Dog Aging Project TRIAD enrollment pageFursBliss does not provide veterinary diagnosis or treatment. Always consult a licensed veterinarian for medication and supplement decisions.
Drug status details are compiled from public announcements and may change.